Results 71 to 80 of about 1,721 (143)

Vericiguat: A Review in Chronic Heart Failure with Reduced Ejection Fraction

, 2022
Declarations Funding The preparation of this review was not supported by any external funding. Authorship and Conflict of interest Connie Kang and Yvette N.
Yvette N. Lamb (5073848), Connie Kang (7248215)   +1 more
core   +1 more source

Clinical Effectiveness and Safety of Vericiguat in Worsening Heart Failure with Reduced Ejection Fraction: A Single-center, Retrospective Analysis in Indian Patients

Journal of the Practice of Cardiovascular Sciences
Background and Objective: In a tertiary care hospital in India, investigators evaluated the efficacy and safety of vericiguat, a new oral soluble guanylate cyclase stimulator in patients with worsening symptoms of heart failure and reduced ejection ...
Pankaj Jariwala, Avvaru Guru Prakash, Poondru Rohith Reddy, Dilip Gude, Gururaj Pramod Kulkarni, Arshad Punjani, Harikishan Boorugu, Dilip Babu Madhawar, Anusha Jariwala   +8 more
doaj   +1 more source

A prospective analysis of management and outcomes of worsening heart failure in the outpatient setting

ESC Heart Failure, Volume 12, Issue 6, Page 3920-3928, December 2025.
Abstract Aims There is growing recognition of the burden and prognostic significance of WHF treated in the outpatient setting. However, there is currently a lack of prospective real‐world data in this area of HF care. This study aims to analyse the natural history of outpatient WHF.
Joseph McCambridge, Fiyinfoluwa Fabamwo, Shadia Taha, Dermot McCaffrey, Matthew Barrett, Ciara Mahon, Kenneth McDonald   +6 more
wiley   +1 more source

Improved endothelial function in heart failure outpatients with reduced ejection fraction after vericiguat therapy

Background Vericiguat, a soluble guanylate cyclase stimulator, has been shown to be effective in improving the prognosis of patients with heart failure with reduced ejection fraction (HFrEF) and worsening heart failure.
Correale Michele, Santagata Federica, Barile Massimo, Furore Andrea, Tesse Martina, Stabile Eugenio, Capasso Raffaele, Brunetti Natale Daniele, Iacoviello Massimo, Nodari Savina, D’Alessandro Damiano, Dattilo Giuseppe, Carbonara Michelangelo, Mazzeo Pietro   +13 more
core   +1 more source

The emerging role of Nrf2 in heart failure: From cardioprotection to therapeutic approaches

ESC Heart Failure, Volume 12, Issue 6, Page 4000-4020, December 2025.
Nrf2 signalling is impaired in heart failure, contributing to oxidative stress, mitochondrial dysfunction, and ferroptosis, which drive neurohormonal activation, inflammation, and ischaemia‐reperfusion injury. This loss of Nrf2 activity exacerbates hypertension, diabetic cardiomyopathy, and cardiotoxicity, accelerating progression to overt heart ...
Emiliano Fiori, Sergio Davinelli, Armando Ferrera, Alessandro Medoro, Carlo Barsali, Allegra Battistoni, Maurizio Volterrani, Massimo Volpe, Luciano Saso, Speranza Rubattu   +9 more
wiley   +1 more source

Vericiguat in patients with heart failure across the spectrum of left ventricular ejection fraction: a patient-level, pooled meta-analysis of VITALITY-HFpEF and VICTORIA

Frontiers in Endocrinology
Vericiguat, the newest soluble guanylate cyclase (sGC) drug, is potentially beneficial in treating heart failure (HF). However, most studies have only confirmed the significant impact of sGC in patients with reduced left ventricular ejection fraction ...
Chao Chen, Jin Lv, Changzhao Liu
doaj   +1 more source

Rationale and design of the vericiguat in vasospastic angina (ViVA) trial:A double-blind placebo-controlled randomized cross-over study

Background Coronary vasospasm is highly prevalent in patients with angina and no obstructive coronary arteries (ANOCA). In the pathophysiology of coronary vasospasm, endothelial dysfunction and vascular smooth muscle cell hyper-reactivity may cause an ...
Boerhout, Coen K. M., Heestermans, Ton A. C. M., den Ruijter, Hester M., Mechroubi, Aimane, Dimitriu-Leen, Aukelien C., Nijkamp, Timo, Escaned, Javier, Meuwissen, Martijn, van de Hoef, Tim P., de Jong, Elize A. M., Appelman, Yolande, Piek, Jan J., Eringa, Etto C., Namba, Hanae F., Vos, Nicola S., Delewi, Ronak, den Haan, Melina C., Damman, Peter, Beijk, Marcel A. M.   +18 more
core   +2 more sources

Efficacy of vericiguat in patients with chronic heart failure and reduced ejection fraction: a prospective observational study

BMC Cardiovascular Disorders
Objectives This study aims to evaluate the therapeutic effect of Vericiguat through cardiopulmonary exercise testing (CPET) in patients with chronic heart failure and reduced ejection fraction (HFrEF).
Yinge Zhan, Liu Li, Jie Zhou, Yishan Ma, Xuchong Guan, Suo Wang, Ya Chang   +6 more
doaj   +1 more source

Vericiguat: A Novel Soluble Guanylate Cyclase Stimulator For Use in Patients with Heart Failure.

, 2022
Heart failure affects 6.2 million Americans and is increasing annually in its frequency. Treatment of heart failure has been at the forefront of medical advancements due to the financial burden on our health care system.
Sood, Aayaan, Aronow, Wilbert S, Rajeswaran, Yasotha, MD, Egeler, David, Lanier, Gregg M, Frishman, William H, Gupta, Rahul, MD, Lin, Muling, Maitz, Theresa, DO, Vyas, Apurva, MD, Ahnert, Amy M, MD   +10 more
core   +1 more source

Cost-utility analysis of add-on vericiguat for the treatment of chronic heart failure with reduced ejection fraction in China

BMC Public Health
Objective This study aimed to evaluate the cost-utility of the addition of vericiguat for treating chronic heart failure (CHF) in China from the healthcare payer’s perspective. Methods A Markov model was built to estimate the cost and utility of treating
Lu Wang, Xuechen Huo, Haiyan Sun, Feiyu Liu, Ruiqin Huang, Quan Zhao   +5 more
doaj   +1 more source